GENTIAN DIAGNOSTICS ASA (GENT.OL) Stock Price, Forecast & Analysis
Europe - Euronext Oslo - OSL:GENT - NO0010748866 - Common Stock
GENT.OL Key Statistics, Chart & Performance
The current stock price of GENT.OL is 58 NOK. In the past month the price increased by 5.84%. In the past year, price increased by 38.76%.
GENT.OL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EL.PA | ESSILORLUXOTTICA | 40.45 | 128.71B | ||
| 1EL.MI | ESSILORLUXOTTICA | 40.28 | 128.15B | ||
| ESL.DE | ESSILORLUXOTTICA | 40.04 | 127.41B | ||
| GBT.PA | GUERBET | 24.67 | 187.07M | ||
| ALCJ.PA | CROSSJECT | N/A | 119.98M | ||
| AFME.PA | AFFLUENT MEDICAL SA | N/A | 73.19M | ||
| PTP.DE | PENTIXAPHARM HOLDING AG | N/A | 47.62M | ||
| SVS.MI | SVAS BIOSANA SPA | 6.43 | 45.70M | ||
| IVN.MI | IVISION TECH SPA | N/A | 13.25M |
Related stock screener links
About GENT.OL
Company Profile
Gentian Diagnostics ASA engages in the research, development, production, marketing, and distribution of immunoassays. The company is headquartered in Moss, Ostfold and currently employs 63 full-time employees. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
Company Info
GENTIAN DIAGNOSTICS ASA
Bjornasveien 5
Moss OSTFOLD NO
Employees: 63
Phone: 4799339905
GENTIAN DIAGNOSTICS ASA / GENT.OL FAQ
Can you describe the business of GENTIAN DIAGNOSTICS ASA?
Gentian Diagnostics ASA engages in the research, development, production, marketing, and distribution of immunoassays. The company is headquartered in Moss, Ostfold and currently employs 63 full-time employees. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
Can you provide the latest stock price for GENTIAN DIAGNOSTICS ASA?
The current stock price of GENT.OL is 58 NOK. The price decreased by -0.34% in the last trading session.
What is the dividend status of GENTIAN DIAGNOSTICS ASA?
GENTIAN DIAGNOSTICS ASA (GENT.OL) has a dividend yield of 0.69%. The yearly dividend amount is currently 0.
What is the ChartMill rating of GENTIAN DIAGNOSTICS ASA stock?
GENT.OL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is GENTIAN DIAGNOSTICS ASA worth?
GENTIAN DIAGNOSTICS ASA (GENT.OL) has a market capitalization of 894.36M NOK. This makes GENT.OL a Small Cap stock.
Can you provide the ownership details for GENT stock?
You can find the ownership structure of GENTIAN DIAGNOSTICS ASA (GENT.OL) on the Ownership tab.
GENT.OL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GENT.OL. When comparing the yearly performance of all stocks, GENT.OL is one of the better performing stocks in the market, outperforming 77.02% of all stocks.
GENT.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GENT.OL. GENT.OL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
GENT.OL Financial Highlights
Over the last trailing twelve months GENT.OL reported a non-GAAP Earnings per Share(EPS) of 2.73. The EPS increased by 2066.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.8% | ||
| ROA | 18.38% | ||
| ROE | 21.18% | ||
| Debt/Equity | 0.01 |
GENT.OL Forecast & Estimates
7 analysts have analysed GENT.OL and the average price target is 68.34 NOK. This implies a price increase of 17.83% is expected in the next year compared to the current price of 58.
For the next year, analysts expect an EPS growth of 59.41% and a revenue growth 31.13% for GENT.OL